BioWorld

Nov. 23, 2009

SPAs on the Rise for Many, Despite Setbacks for a Few

Twice this month, biotechs that achieved their primary endpoints in a pivotal trial conducted under a special protocol assessment (SPA) found their drugs turned down by the FDA. Read More

Of Vivus and Viagra: Could Patent Expiry Rattle ED Bid?

Money Raised Year to Date

Money Raised By Biotech in 2009

Week in Review

Word on the Street

Biotechnology Company Deals With Other Biotechnology Companies: October 1 - November 19, 2009

Manufacturing, Marketing And Distribution Agreements Between Biotech Companies: October 1 - November 19, 2009

Biotech - Biotech Collaborations: Modified Agreements: October 1 - November 19, 2009

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for July 15, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Photo of scale with woman sitting on floor holding head and arms on knees

Rethinking anorexia: A disorder of mind and metabolism

BioWorld Science

Anorexia nervosa (AN) is a complex and severe eating disorder that has long been considered a psychiatric condition driven by distorted body image and maladaptive...